Introducing the South African Rare Diseases Access Initiative
DOI:
https://doi.org/10.7196/SAMJ.2023.v113i8.1142Keywords:
rare diseases, healthcare access, South Africa, diagnostics, careAbstract
-
References
Orphanet. Prevalence and incidence of rare diseases: Bibliographic data. Diseases listed by decreasing
prevalence, incidence or number of published cases. Paris: Orphanet, 2022. https://www.orpha.net/
orphacom/cahiers/docs/GB/Prevalence_of_rare_diseases_by_decreasing_prevalence_or_cases.pdf
(accessed 5 March 2022).
European Organisation on Rare Diseases. Rare diseases: Understanding this public health priority.
Paris: EURORDIS, 2005. https://www.eurordis.org/wp-content/uploads/2009/12/princeps_
document-EN.pdf (accessed 23 April 2023).
Haendel M, Vasilevsky N, Unni D, et al. How many rare diseases are there? Nat Rev Drug Discov
;19(2):77-78. https://doi.org/10.1038/d41573-019-00180-y
Rare Diseases International. Operational Description of Rare Diseases. A Reference to Improve the
Recognition and Visibility of Rare Diseases. Paris: RDI, 2022. https://www.rarediseasesinternational.
org/description-for-rd/ (accessed 30 March 2022).
Statistics South Africa. Statistical Release P0302. Mid-year population estimates 2022. Pretoria: StatsSA,
https://www.statssa.gov.za/publications/P0305/P03052021.pdf (accessed 20 February 2023).
Council of the European Union. Council recommendation on action in the field of rare diseases. J Eur
Comm 2009:C151/7-C151/10. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex%3A3200
H0703%2802%29 (accessed 23 April 2023).
Wakap SN, Lambert DM, Olry A, et al. Estimating cumulative point prevalence of rare diseases:
Analysis of the Orphanet database. Eur J Hum Genet 2020;28(2):165-173. https://doi.org/10.1038/
s41431-019-0508-0
Black N, Martineau F, Manacorda T. Diagnostic odyssey for rare diseases: Exploration of potential
indicators. Policy Innovation Research Unit. London: School of Hygiene and Tropical Medicine, 2015.
https://piru.ac.uk/assets/files/Rare%20diseases%20Final%20report.pdf (accessed 23 April 2023).
US Food and Drug Administration. Rare disease cures accelerator – to support innovation and quality
in rare disease drug development USA. Maryland: FDA, 2022. https://www.fda.gov/drugs/regulatoryscience-research-and-education/rare-disease-cures-accelerator (accessed 23 April 2023).
Rare Diseases Access Initiative. Call for a National Rare Disease Framework. Johannesburg: Rare
Diseases South Africa, 2020.
Rare Diseases Access Initiative. Workshop Report: Rare Diseases Access Initiative (RDAI): ‘Advancing
into Action’. 27 October 2022. Johannesburg: Rare Diseases South Africa, 2023.
National Department of Health, South Africa. National Health Insurance Policy for National Health
Act No. 61 of 2003. Towards Universal Health Coverage. Government Gazette No. 40955:627. Pretoria:
NDoH, 2017.
United Nations General Assembly. Sustainable Development Goal 3: Ensure Healthy Lives and Promote
Wellbeing for All and at All Ages. Geneva:
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Helen Malherbe
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Licensing Information
The SAMJ is published under an Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
Publishing Rights
Authors grant the Publisher the exclusive right to publish, display, reproduce and/or distribute the Work in print and electronic format and in any medium known or hereafter developed, including for commercial use. The Author also agrees that the Publisher may retain in print or electronic format more than one copy of the Work for the purpose of preservation, security and back-up.
